Ritu Salani, MD, MBA, UCLA Health in Los Angeles, CA, discusses the promising future of immunotherapy in the management of uterine cancer, highlighting the potential for immunotherapy to lead to cures and improved survival outcomes for patients. Prof. Salani emphasizes the importance of clinical trials in exploring innovative approaches, such as re-challenging with immunotherapy, and investigating other biomarkers beyond immune-related ones, such as alpha, folate receptor, and trop two. She underscores the need for subgroup analysis to better understand heterogeneous patient populations and tailor treatments accordingly. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
